Aurinia Pharmaceuticals Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Aurinia Pharmaceuticals Inc. (AUPH) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $934.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2024-11-07
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-09-30 was $651.00K, a 93.84% decline year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-06-30 was $6.88M, a 28.25% increase year-over-year.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2024-03-31 was -$6.59M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2023-12-31 was $1.58M.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $13.39M, a 1816.17% increase from fiscal 2022.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $699.00K, a 82.85% decline from fiscal 2021.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $4.08M, a 70.07% decline from fiscal 2020.
- Aurinia Pharmaceuticals Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2020 was $13.62M, a 239.99% increase from fiscal 2019.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2024-09-30 | $651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.53M derived: sum of 2 quarters · filed 2024-11-07 | $934.00K 10-Q · filed 2024-11-07 | $2.52M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $6.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $283.00K 10-Q · filed 2024-08-01 | $1.86M derived: sum of 3 quarters · filed 2024-08-01 | $12.43M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | -$6.59M 10-Q · filed 2024-05-02 | -$5.01M derived: sum of 2 quarters · filed 2024-05-02 | $5.55M derived: sum of 3 quarters · filed 2024-11-07 | $10.92M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $12.15M derived: sum of 2 quarters · filed 2024-11-07 | $17.51M derived: sum of 3 quarters · filed 2024-11-07 | $13.39M 10-K · filed 2024-02-15 |
| 2023-09-30 | $10.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $15.93M derived: sum of 2 quarters · filed 2024-11-07 | $11.81M 10-Q · filed 2024-11-07 | $11.64M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $1.25M 10-Q · filed 2024-08-01 | $1.07M derived: sum of 3 quarters · filed 2024-08-01 | $8.19M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$4.12M 10-Q · filed 2024-05-02 | -$4.29M derived: sum of 2 quarters · filed 2024-05-02 | $2.82M derived: sum of 3 quarters · filed 2024-05-02 | $3.29M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $6.94M derived: sum of 2 quarters · filed 2024-02-15 | $7.40M derived: sum of 3 quarters · filed 2024-02-15 | $699.00K 10-K · filed 2024-02-15 |
| 2022-09-30 | $7.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.58M derived: sum of 2 quarters · filed 2023-11-02 | $875.00K 10-Q · filed 2023-11-02 | $3.80M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $462.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$6.24M 10-Q · filed 2023-08-03 | -$3.31M derived: sum of 3 quarters · filed 2024-02-15 | -$3.20M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$6.70M 10-Q · filed 2023-05-04 | -$3.78M derived: sum of 2 quarters · filed 2024-02-15 | -$3.66M derived: sum of 3 quarters · filed 2024-02-15 | $4.47M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $3.04M derived: sum of 2 quarters · filed 2024-02-15 | $11.18M derived: sum of 3 quarters · filed 2024-02-15 | $4.08M 10-K · filed 2024-02-15 |
| 2021-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $8.25M derived: sum of 2 quarters · filed 2022-11-03 | $1.15M 10-Q · filed 2022-11-03 | $5.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $8.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.03M 10-Q · filed 2022-08-04 | $5.64M derived: sum of 3 quarters · filed 2023-02-28 | $12.19M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$7.10M 10-Q · filed 2022-05-10 | -$2.50M derived: sum of 2 quarters · filed 2023-02-28 | $4.05M derived: sum of 3 quarters · filed 2023-02-28 | $5.28M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $4.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $11.16M derived: sum of 2 quarters · filed 2023-02-28 | $12.39M derived: sum of 3 quarters · filed 2023-02-28 | $13.62M 10-K · filed 2023-02-28 |
| 2020-09-30 | $6.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $7.78M derived: sum of 2 quarters · filed 2021-11-03 | $9.01M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.46M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $1.23M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $4.01M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$887.00K 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |